Pachyonychia congenita (PC) is an autosomal dominant genodermatosis caused by heterozygous mutations in any one of the genes encoding the differentiation-specific keratins K6a, K6b, K16, or K17.
The main clinical features of the condition include painful and highly debilitating plantar keratoderma, hypertrophic nail dystrophy, oral leukokeratosis, and a variety of epidermal cysts. Although the condition has previously been subdivided into PC-1 and PC-2 subtypes, the phenotypic characterization of 1,000 mutation-verified PC patients enrolled in the International PC Research Registry, coordinated by the patient advocacy group PC Project, shows that there is considerable overlap between these subtypes. Thus, a new genotypic nomenclature is proposed, in which PC-6a represents a patient carrying a mutation in the K6a gene, etc. Although a rare disorder, PC represents a good model for therapy development, and international efforts are ongoing to develop and deliver siRNA, gene, correction, small molecule, and other strategies to treat this painful, disabling skin condition. The special relationship between PC Project and the PC research community has greatly accelerated the development pathway from gene identification to clinical trials in only a few years and represents a paradigm of hope for other orphan diseases.
INTRODUCTION
Pachyonychia congenita (PC) is an uncommon autosomal dominant disorder of keratinization caused by mutations in any one of a number of keratin genes that are expressed in differentiated epithelial tissues. The condition was first described in the early twentieth century (Jadassohn and Lewandowski, 1906; Jackson and Lawler, 1951) but it was not until the early 1990s, with the emergence of molecular genetics technology, that the causative gene in a large Scottish PC family was mapped to one of the keratin gene clusters (Munro et al., 1994) . Shortly thereafter, the causative mutations were identified in several PC patients in the KRT6A, KRT6B, KRT16, and KRT17 genes, encoding the keratin proteins K6a, K6b, K16, and K17, respectively (Bowden et al., 1995; McLean et al., 1995; Smith et al., 1998) . Keratins are the intermediate filament proteins specifically expressed by epithelial cells, in which they form a dense cytoplasmic network (Irvine and McLean, 1999; Omary et al., 2004) . The primary function of the keratin cytoskeleton is to impart mechanical strength and resilience to epithelial cells and tissues. Disruption of this cytoskeletal system due to a genetic mutation in a keratin gene leads to extreme fragility of the epithelial cells and tissues in which the mutated keratin is expressed. Similar to several other keratin disorders, the vast majority of causative mutations in the PC-related keratins are heterozygous missense mutations or small insertion/ deletion mutations that disrupt cytoskeletal function via dominant-negative interference and lead to epithelial cell fragility (McLean et al., 2005) . In PC, this is manifest as cytolysis and hyperkeratosis in the subset of differentiated epithelial tissues in which K6a, K6b, K16, and K17 are predominantly expressed (Lane, 1993) , specifically the palmoplantar epidermis, nail bed, mucosae, and the pilosebaceous unit. Thus, the cardinal phenotypic features of PC are palmoplantar (predominantly plantar) keratoderma; hypertrophic nail dystrophy; oral leukokeratosis; and a variety of cysts arising from hyperkeratosis of pilosebaceous apparatus ( Figure 1 ).
A MOLECULAR CLASSIFICATION FOR PC SUBTYPES
In 2003, a patient advocacy group-Pachyonychia Congenita Project-was established to support those affected by PC and to both encourage and fund research into a cure for the condition (www.pachyonychia.org). To achieve this goal, the International PC Consortium (IPCC) was founded in early 2004. This is a group of clinicians and scientists actively researching the causes of PC and importantly, the development of new treatments for PC. The IPCC has met annually since 2004 and its membership is listed at www.pachyonychia.org.
An important part of the ongoing PC research program is the International PC Research Registry (IPCRR), in which detailed phenotypic data are collected from patients and linked to genetic data. At the time of writing, close to 1000 PC patients have been identified by the PC Project. This has led to the largest collection of linked clinical and genetic information yet assembled for a rare keratin disorder. Historically, PC has been split into two subtypes (PC-1, or Jadassohn-Lewandowski subtype; and PC-2, or the Jackson--Lawler subtype) on the basis of subtle differences in phenotype, primarily the presence or absence of pilosebaceous cysts (Jadassohn and Lewandowski, 1906; Jackson and Lawler, 1951) . At present, with analysis of hundreds of patients in the IPCRR, limitations in the older classification, which was based on only a handful of non-genotyped cases, have become clear. In particular, many PC patients, regardless of genotype, have some form of epidermal cysts (see Wilson et al., 2011) . Therefore, on the basis of the more comprehensive IPCRR data, a more rational and useful classification based on the mutated gene was proposed at the 2010 IPCC Symposium and has been adopted throughout the research papers in this issue of the JID. The new classification is PC-6a, PC-6b, PC-16, and PC-17, for a patient with a mutation in the gene encoding K6a and others proteins (the complete data set underlying this new nomenclature will be published elsewhere; Eliason et al., unpublished data). In cases in whom PC is suspected but no mutation has been found (or not looked for), the term PC-U (for unknown) will be used.
The predominant symptom in PC is plantar pain
Although hypertrophic nail dystrophy is the phenotypic feature that gave rise to the name of the condition, the most problematic symptom reported by PC patients is focal plantar keratoderma that is associated with severe pain. The plantar pain in PC is often highly debilitating and has considerable negative effect on quality of life. The reason for the pain is not fully understood but is thought to be related to blister formation deep underneath the thick callus that develops over the pressure points of the plantar surface (see Figure 1a) . Plantar blistering, together with accompanying pain, is a common feature of PC that is under-reported in the literature (Eliason et al., unpublished data) .
Nail dystrophy (Figure 1b) , which can occur from a very early age, is variable in severity and in many cases not all 20 nails are affected. Toenails are more commonly affected than fingernails, which could be because of greater trauma exerted from shoes. Another feature of PC is oral leukokeratosis (Figure 1c ). This is often one of the first signs of PC in babies and may lead to difficulty in feeding and is often mistaken for candidiasis in infants. Follicular keratoses are present in many cases of PC. Some individuals also develop cysts in the form of steatocysts (steatocystomas) and/or pilosebaceous cysts (Figure 1d ). This feature is particularly associated with patients with a K17 mutation (see Wilson et al., this issue) , in whom sometimes it is necessary to remove cysts surgically. The severity of the clinical features of PC can vary quite widely both among and within families. This may partly be because of individual lifestyle and care of PC and could also be because of the specific type of mutation, as well as other genetic and/or environmental factors. Although it is a rare condition, PC is at the forefront of genetic therapy development in the dermatology field.
In particular, the dominant-negative genetic mechanism in PC contributes to therapeutic strategies based on RNA interference (RNAi), especially in the form of short interfering RNA (siRNA). It has been demonstrated that mutant keratin alleles differing from wild type by a single-nucleotide point mutation can be potently and specifically silenced by carefully designed siRNA . This mutation-specific siRNA therapy approach has been progressed into the recently reported small-scale human clinical trial, in which efficacy was demonstrated (Leachman et al., 2010) . This was the first time that siRNA had been used to treat a human skin disorder. The keratins involved in PC also show considerable functional redundancy, in particular when K6 is involved. Humans have three copies of a nearly identical KRT6 gene, encoding the K6a, K6b, and K6c proteins. Mouse knockout experiments strongly suggest that loss of one of these keratins may be tolerated (Wong et al., 2000; Wojcik et al., 2001) and therefore an alternative therapeutic approach would be to completely silence the defective keratin, regardless of mutation. To this end, highly potent gene-specific siRNA has been developed for PC . The major technical hurdle yet to overcome in both these therapeutic approaches is the development of a safe, effective, and patient-friendly method for routine delivery of siRNA into the epidermis. This is currently a major goal of the IPCC research groups, in addition to development of alternative therapies that include gene correction methodology, small molecule therapy, and other strategies (Kaspar et al., this issue) .
CONCLUSION
Over the past 7 years, the PC research field represents a great example of how a small group of highly motivated patients and their families, together with a group of interested clinicians and scientists, can rapidly progress research from knowing only the identity of a gene defect to having new therapies that show efficacy in cells, in animal models, and in patients. Hopefully, this sustained, highly focused effort will shortly lead to a successful and widely applicable treatment for PC and the lessons learned along the way can be translated to other genetic skin disorders.
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